1. Home
  2. Stocks
  3. Syncomf Share Price

Syncom Formulation (India) Share Price

Pharmaceuticals Small Cap

₹20.77 +0.44 (2.16%)

05 Nov, 2024 17:25

SIP TrendupStart SIP in SYNCOMF

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹20
  • High
  • ₹21
  • 52 Week Low
  • ₹9
  • 52 Week High
  • ₹28
  • Open Price₹20
  • Previous Close₹20
  • Volume3,353,024

Investment Returns

  • Over 1 Month -0.43%
  • Over 3 Month + 31.71%
  • Over 6 Month + 48.89%
  • Over 1 Year + 134.69%
SIP Lightning

Smart Investing Starts Here Start SIP with Syncom Formulation (India) for Steady Growth!

Syncom Formulation (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 68.4
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 1,952
  • P/B Ratio
  • 6.8
  • Average True Range
  • 1.22
  • EPS
  • 0.2
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.45
  • RSI
  • 49.39
  • MFI
  • 41.81

Syncom Formulation (India) Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations86.8373.2763.3462.3959.36
Total Income From Operations86.8373.2763.3462.3959.36
P/L Before Interest, Excpt. Items & Tax10.4810.389.709.226.94
P/L Before Exceptional Items & Tax10.109.218.628.145.81
P/L After Tax from Ordinary Activities7.636.756.426.214.25
Net Profit/Loss For the Period7.636.756.426.214.25
IndicatorMar 24Mar 23
Revenue From Operations [Gross]254.90222.88
Revenue From Operations [Net]254.90222.88
Total Operating Revenues258.36224.64
Total Revenue271.46239.25
Total Expenses239.68212.70
Profit/Loss Before Tax31.7626.57
Profit/Loss For The Period23.6220.07
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-5.9410.50
Net Cash Used In Investing Activity83.83-44.97
Net Cash Used in Finance Activity-15.3735.00
Net Inc/Dec In Cash And Equivalent62.520.53
Cash And Equivalent End Of Year63.350.83
IndicatorMar 24Mar 23
Total Share Capital94.0094.00
Total Non-Current Liabilities10.008.66
Total Current Liabilities95.05112.27
Total Capital And Liabilities391.50376.94
Total Non-Current Assets128.86196.17
Total Current Assets262.64180.77
Total Assets391.50376.94
Indicator20242023
EBIT Margin (%)14.0213.21
Return On Capital Employed (%)12.2211.21
Return On Equity (%)8.247.83
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)3.052.72
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations87.2674.5765.1463.8459.84
Total Income From Operations87.2674.5765.1463.8459.84
P/L Before Interest, Excpt. Items & Tax10.4911.2310.479.527.23
P/L Before Exceptional Items & Tax10.1010.039.398.456.11
P/L After Tax from Ordinary Activities7.637.407.006.514.40
Net Profit/Loss For the Period7.637.407.006.514.40
IndicatorMar 24Mar 23
Revenue From Operations [Gross]259.24222.49
Revenue From Operations [Net]259.24222.49
Total Operating Revenues263.39224.25
Total Revenue276.91238.85
Total Expenses242.94212.29
Profit/Loss Before Tax33.9526.57
Profit/Loss For The Period25.3120.07
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-5.9610.53
Net Cash Used In Investing Activity83.02-44.95
Net Cash Used in Finance Activity-14.5635.00
Net Inc/Dec In Cash And Equivalent62.500.58
Cash And Equivalent End Of Year63.380.88
IndicatorMar 24Mar 23
Total Share Capital94.0094.00
Total Non-Current Liabilities10.008.66
Total Current Liabilities106.52113.16
Total Capital And Liabilities404.66377.83
Total Non-Current Assets129.88196.14
Total Current Assets274.78181.69
Total Assets404.66377.83
Indicator20242023
EBIT Margin (%)14.5913.23
Return On Capital Employed (%)12.8911.21
Return On Equity (%)8.787.83
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)3.072.72

Syncom Formulation (India) Technicals

EMA & SMA

Current Price
₹20.77
+ 0.44 (2.16%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹20.29
  • 50 Day
  • ₹20.18
  • 100 Day
  • ₹18.70
  • 200 Day
  • ₹16.43

Resistance and Support

20.5 Pivot Speed
  • R3 22.18
  • R2 21.68
  • R1 21.00
  • S1 19.82
  • S2 19.32
  • S3 18.64

Is Syncom Formulation (India) Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Syncom Formulations Ltd. manufactures pharmaceutical products, including tablets, capsules, syrups, and ointments. Serving both domestic and international markets, it offers a broad range of affordable, high-quality medicines across therapeutic segments like antibiotics, pain relief, and vitamins. Syncom Formulations India has an operating revenue of Rs. 290.81 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 27% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Syncom Formulation (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-17 Audited Results
2024-02-14 Quarterly Results
2023-11-08 Quarterly Results

Syncom Formulation (India) F&O

Syncom Formulation (India) Shareholding Pattern

50.57%
0%
0.1%
45.15%
4.18%
  • NSE Symbol
  • SYNCOMF
  • BSE Symbol
  • 524470
  • Managing Director
  • Mr. Vijay Shankarlal Bankda
  • ISIN
  • INE312C01025

Syncom Formulation (India) FAQs

Syncom Formulation (India) share price is ₹20 As on 05 November, 2024 | 17:11

The Market Cap of Syncom Formulation (India) is ₹1952.4 Cr As on 05 November, 2024 | 17:11

The P/E ratio of Syncom Formulation (India) is 68.4 As on 05 November, 2024 | 17:11

The PB ratio of Syncom Formulation (India) is 6.8 As on 05 November, 2024 | 17:11

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.